Sep 19, 2014 at 08:22 | Source: CNBC-TV18
Tata Motors | Tata Chemicals | Tata Steel | Tata Power | Tech Mahindra | Bosch | GTL Infrastructure | SBI | Axis Bank | ICICI Bank | Manappuram Finance | United Spirits | Zee Entertainment | MCX India | SPML Infra | Cipla and Biocon are stocks, which are in the news today.
Sep 16, 2014 at 17:51 | Source: Moneycontrol.com
Wockhardt has informed that the Board of Directors of the Company at its meeting held on September 15, 2014, approved a scheme of Amalgamation for amalgamation/merger of following two wholly owned subsidiaries with the Company: 1. Wockhardt Biopharm Limited (WBL) and 2. Vinton Healthcare Limited (VHL).
Sep 16, 2014 at 14:23 | Source: Moneycontrol.com
"Zydus Cadila has received tentative approval from the US Food and Drug Administration (US FDA) to market (anti-diabetic drug) Glipizide extended release tablets in the strength of 2.5 mg, 5 mg and 10 mg," said the company in its filing.
Sep 16, 2014 at 09:57 | Source: CNBC-TV18
Neelkanth Mishra, Credit Suisse says consumption remains a secular growth story in India with years of catch up to even other emerging markets.
Sep 15, 2014 at 19:55 | Source: CNBC-TV18
US healthcare clients are desperate to cut costs and therefore, there cannot be a better time than today to buy TriZetto, says Gordon Coburn, President, Cognizant.
Sep 15, 2014 at 16:13 | Source: CNBC-TV18
The acquisition will position Cognizant to address the rapidly changing healthcare marketplace that currently holds 17 percent of the US GDP.
Sep 15, 2014 at 15:32 | Source: CNBC-TV18
Phani Sekhar, Fund Manager-PMS at Angel Broking feels that Fortis Healthcare may add 10-15 percent.
Sep 15, 2014 at 13:21 | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com recommends buying Fortis Healthcare with a view of one year.
Sep 15, 2014 at 13:10 | Source: CNBC-TV18
Here are the top buzzing stocks of Sep 15 -Fortis healthcare, Mastek, Nitesh Estates, Just dial, Cipla.
Sep 15, 2014 at 12:36 | Source: Moneycontrol.com
The Street is building in a capex cycle of the likes in 2004 and 2008, Elara says, adding, while we do not dispute the recovery signals, we are circumspect of the relative outperformance of cyclicals over the medium term (12 months).